CD8A and B-cell chronic lymphocytic leukemia: In addition to selectively causing the death of malignant cells, such as chronic lymphocytic leukemia (CLL), recent reports suggest that venetoclax augments both CD8 and NK cell killing of malignant cells (41, 42).